Results 21 to 30 of about 8,112 (240)

Personalized biological treatment with lanadelumab in a patient with recurrent attacks of hereditary angioedema [PDF]

open access: yesAlergologia Polska
Hereditary angioedema (HAE) is an autosomal dominantly inherited disease caused by deficiency of C1 esterase inhibitor protein type 1 (about 85% of patients with HAE-C1-INH) or type 2 oedema (about 15% of patients with HAE-C1-INH) by C1 inhibitor ...
Artur Gęsicki   +6 more
doaj   +2 more sources

Hereditary angioedema: a disease seldom diagnosed by pediatricians

open access: yesJornal de Pediatria, 2021
Objectives: To describe the hereditary angioedema to improve awareness of this condition and reduce diagnostic delay. Data sources: Relevant articles in the MEDLINE database through PubMed.
Régis de Albuquerque Campos   +2 more
doaj   +1 more source

Outcomes of long term treatments of type I hereditary angioedema in a Turkish family [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2017
: Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks.
Gulsen Akoglu   +3 more
doaj   +2 more sources

A patient with hereditary angioedema and systemic lupus erythematosus: Coincidence or coexistence?

open access: yesMedicine Science, 2020
Angioedema is classified into two major groups: mast cell-mediated (histaminergic) and bradykinin-mediated angioedema. Hereditary angioedema and acquired angioedema are well-defined groups of bradykinin-mediated angioedema. Both hereditary angioedema and
Gokhan Aytekin   +3 more
doaj   +1 more source

Recurrent angioedema in childhood: hereditary angioedema or histaminergic angioedema? [PDF]

open access: yes, 2021
Background Recurrent angioedema is a rare entity during childhood. This study aimed to clarify differences between hereditary angioedema (HAE) and histaminergic angioedema (HA) in ...
ŞAHİNER, ÜMİT MURAT   +13 more
core   +1 more source

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

open access: yesJournal of Allergy and Clinical Immunology: Global, 2023
We report an approximately 80% reduction in angioedema attacks with lanadelumab, a mAb targeting plasma kallikrein, in a case of hereditary angioedema with normal C1 inhibitor levels.
Adil Adatia, MD, Bruce Ritchie, MD
doaj   +1 more source

Hereditary angioedema (HAE) in children and adolescents : a consensus on therapeutic strategies [PDF]

open access: yes, 2012
Hereditary angioedema due to C1 inhibitor (C1 esterase inhibitor) deficiency (types I and II HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema ...
Martinez-Saguer, I   +35 more
core   +1 more source

Pathophysiology and underlying mechanisms in hereditary angioedema. [PDF]

open access: yes, 2021
This review aims to summarize the main pathophysiological events involved in the development of hereditary angioedema (OMIM#106100). Hereditary angioedema is a rare genetic disease inherited in an autosomal dominant manner and caused by a loss of control
López Lera, Alberto
core   +1 more source

Treatment of Hereditary Angioedema [PDF]

open access: yesJournal of Investigational Allergology and Clinical Immunology, 2021
Hereditary angioedema due to C1-esterase inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant disease. In the last decade, new drugs and new indications for old drugs have played a role in the management of C1-INH-HAE. This review examines current therapy for C1-INH-HAE and provides a brief summary of drugs that are under development ...
openaire   +2 more sources

WAO guideline for the management of hereditary angioedema [PDF]

open access: yes, 2012
Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers.
Ruby Pawankar   +39 more
core   +1 more source

Home - About - Disclaimer - Privacy